OBJECTIVE: Bacterial vaginosis (BV) is associated with preterm delivery, but there is little evidence that treatment improves pregnancy outcomes. We examined whether oral or vaginal metronidazole treatment for BV in early pregnancy was more effective in restoring the normal vaginal environment. METHODS: This was a randomized controlled trial comparing oral and intravaginal metronidazole for treatment of BV in early pregnancy (<20 weeks). Vaginal samples collected at baseline and 4 weeks after treatment were evaluated using gram stain, culture, colorimetric detection of sialidase, and immunoassay for measurement of proinflammatory cytokines interleukins-1beta, -6, -8 (IL-1beta, IL-6, IL-8) and secretory leukocyte protease inhibitor (SLPI). We compared the effect of treatment between groups (using chi-square and t test) and within individuals (McNemar's test). RESULTS:Of 126 subjects, 108 (86%) completed follow-up (55 oral, 53 intravaginal). Of the study population, 34% achieved therapeutic cure, and this was not different between treatment groups. BV-associated bacteria were significantly reduced in both groups, but few subjects regained colonization with protective lactobacilli. Among women who achieved therapeutic cure, the level of IL-1beta dropped significantly (p < 0.001) and SLPI increased (p = 0.003). More women in the vaginal treatment group had undetectable sialidase after treatment (p = 0.013). CONCLUSIONS: Treatment with oral or intravaginal metronidazole in early pregnancy reduced colonization with BV-associated bacteria but was not effective in achieving therapeutic cure or in restoring healthy vaginal lactobacilli.
RCT Entities:
OBJECTIVE:Bacterial vaginosis (BV) is associated with preterm delivery, but there is little evidence that treatment improves pregnancy outcomes. We examined whether oral or vaginal metronidazole treatment for BV in early pregnancy was more effective in restoring the normal vaginal environment. METHODS: This was a randomized controlled trial comparing oral and intravaginal metronidazole for treatment of BV in early pregnancy (<20 weeks). Vaginal samples collected at baseline and 4 weeks after treatment were evaluated using gram stain, culture, colorimetric detection of sialidase, and immunoassay for measurement of proinflammatory cytokines interleukins-1beta, -6, -8 (IL-1beta, IL-6, IL-8) and secretory leukocyte protease inhibitor (SLPI). We compared the effect of treatment between groups (using chi-square and t test) and within individuals (McNemar's test). RESULTS: Of 126 subjects, 108 (86%) completed follow-up (55 oral, 53 intravaginal). Of the study population, 34% achieved therapeutic cure, and this was not different between treatment groups. BV-associated bacteria were significantly reduced in both groups, but few subjects regained colonization with protective lactobacilli. Among women who achieved therapeutic cure, the level of IL-1beta dropped significantly (p < 0.001) and SLPI increased (p = 0.003). More women in the vaginal treatment group had undetectable sialidase after treatment (p = 0.013). CONCLUSIONS: Treatment with oral or intravaginal metronidazole in early pregnancy reduced colonization with BV-associated bacteria but was not effective in achieving therapeutic cure or in restoring healthy vaginal lactobacilli.
Authors: C Vogelmeier; R C Hubbard; G A Fells; H P Schnebli; R C Thompson; H Fritz; R G Crystal Journal: J Clin Invest Date: 1991-02 Impact factor: 14.808
Authors: Mehmet R Genc; Steven S Witkin; Mary L Delaney; Lilly-Rose Paraskevas; Ruth E Tuomala; Errol R Norwitz; Andrew B Onderdonk Journal: Am J Obstet Gynecol Date: 2004-05 Impact factor: 8.661
Authors: Maria L Alcaide; Violeta J Rodriguez; Megan R Brown; Suresh Pallikkuth; Kristopher Arheart; Octavio Martinez; Margaret Roach; Raina N Fichorova; Deborah L Jones; Savita Pahwa; Margaret A Fischl Journal: AIDS Res Hum Retroviruses Date: 2017-01-03 Impact factor: 2.205
Authors: Andrea Ries Thurman; Thomas Kimble; Betsy Herold; Pedro M M Mesquita; Raina N Fichorova; Hassan Y Dawood; Titilayo Fashemi; Neelima Chandra; Lorna Rabe; Tina D Cunningham; Sharon Anderson; Jill Schwartz; Gustavo Doncel Journal: AIDS Res Hum Retroviruses Date: 2015-07-23 Impact factor: 2.205
Authors: Michelle D Cherne; Amy L Cole; Lisa Newberry; Mary Schmidt-Owens; Michael Deichen; Alexander M Cole Journal: Infect Immun Date: 2020-03-23 Impact factor: 3.441
Authors: Muriel Aldunate; Daniela Srbinovski; Anna C Hearps; Catherine F Latham; Paul A Ramsland; Raffi Gugasyan; Richard A Cone; Gilda Tachedjian Journal: Front Physiol Date: 2015-06-02 Impact factor: 4.566
Authors: Brahm Seymour Coler; Oksana Shynlova; Adam Boros-Rausch; Stephen Lye; Stephen McCartney; Kelycia B Leimert; Wendy Xu; Sylvain Chemtob; David Olson; Miranda Li; Emily Huebner; Anna Curtin; Alisa Kachikis; Leah Savitsky; Jonathan W Paul; Roger Smith; Kristina M Adams Waldorf Journal: J Clin Med Date: 2021-06-29 Impact factor: 4.241